Canavan

TuxCare Names Michael Canavan as Chief Revenue Officer

Retrieved on: 
Tuesday, July 25, 2023
Security, Data Management, Apps, Applications, Technology, Software, Psychology, Canavan, Marketing, Absolute Software Corporation, AlmaLinux, Business, Organization, CloudLinux OS, Trend Micro, Purdue University, Linux, Kaspersky Lab, Economics, Fine chemical, Management, Globalscape

TuxCare , global innovator in enterprise-grade cybersecurity for Linux, today announced the appointment of Michael Canavan as the company’s new Chief Revenue Officer (CRO).

Key Points: 
  • TuxCare , global innovator in enterprise-grade cybersecurity for Linux, today announced the appointment of Michael Canavan as the company’s new Chief Revenue Officer (CRO).
  • Canavan previously served as TuxCare’s senior vice president of global sales.
  • His promotion follows a fast-paced period of worldwide expansion for TuxCare, including new strategic partnerships and the opening of operations outside of the United States.
  • Prior to joining TuxCare in 2021, Canavan served in top sales roles at numerous leading technology companies such as Absolute Software, Globalscape, Kaspersky and Trend Micro.

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Monday, May 22, 2023
Canavan disease, Natural history, Urine, In vivo magnetic resonance spectroscopy, PALO, Brain, DSM-IV codes, Biomarker, Cerebrospinal fluid, NAA, MRI, Magnetic resonance imaging, Cerebellum, Patient, Physician, DSMC, Data, Cancer, White matter, CSF, Hospital, FDA, Massachusetts General Hospital, Therapy, Medical imaging, Pharmaceutical industry, Vaccine, Canavan

“Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.

Key Points: 
  • “Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.
  • The changes in key biomarkers, brain myelination and – critically – clinical function observed in children receiving BBP-812 in our study are compelling, and as we continue to advance our program we are hopeful that we will see outcomes that make a meaningful difference in the lives of children with Canavan disease and their families,” said Genevieve Laforet, M.D., Ph.D., vice president of clinical development at Aspa Therapeutics, the BridgeBio affiliate that is developing BBP-812 for Canavan disease.
  • “We are beyond grateful to the children and their families who are participating in CANaspire as well as the study investigators, who together are making it possible to explore the potential of BBP-812 as a therapy for Canavan disease.
  • Across individual participants, percent decreases in NAA from baseline ranged between 70% and 95% in cerebrospinal fluid (CSF), 29% and 88% in urine, and 8% and 75% in brain (by magnetic resonance spectroscopy)
    All participants in the CANaspire trial had urine NAA levels consistent with typical Canavan disease prior to receiving BBP-812.

Myrtelle to Host Symposium on Gene Therapies Targeting Oligodendrocytes and Implications in Brain Function and Disease States at the American Society of Gene and Cell Therapy 26th Annual Meeting in Los Angeles on Friday, May 19, 2023

Retrieved on: 
Wednesday, May 10, 2023
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, CD, Learning, Neuron, Canavan disease, Inc., University, Gene, Senior, Boonshoft School of Medicine, Clinical trial, Neuroscience, Brain, Cell, Multiple sclerosis, DSM-IV codes, Associate, Assistant, Cerebral cortex, Chromosome 11, Wright, Rita Raave, Leukodystrophy, Neurology, FIH, Patient, Society, Vaccine, Canavan, Myrtelle Canavan, Medicine

The symposium will highlight historical and emerging views of oligodendrocytes in normal brain function and a growing array of disease states, including leukodystrophies and disorders of myelin production such as multiple sclerosis.

Key Points: 
  • The symposium will highlight historical and emerging views of oligodendrocytes in normal brain function and a growing array of disease states, including leukodystrophies and disorders of myelin production such as multiple sclerosis.
  • Oligodendrocytes perform numerous key functions in the brain - including the production of myelin, the insulating material that enables proper neuronal function – and are now appreciated as having roles in a range of diseases.
  • Myrtelle is developing a unique toolkit, including a proprietary class of recombinant adeno-associated virus (rAAV) vectors that directly target these cells.
  • “Given the intractable nature of many neurological diseases, these cells represent important brain components worthy of interrogation in the quest for novel interventions, including gene therapies.

Leading Environmental Lawyer Paul R. McIntyre Returns to Greenberg Traurig in Philadelphia

Retrieved on: 
Thursday, January 26, 2023
University, Villanova University, Postgraduate education, Elon University, LLP, Wake Forest University, P.C, George Washington University Law School, O'Neill dynasty, Churn, Germantown Academy, Penn State Law, Sale, Work, Douglas v. U.S. District Court ex rel Talk America, Insurance, Growth, Vermont Law and Graduate School, Virginia School for Girls, McIntyre, Eye, Wildcat, Acquisition, Alston & Bird, Annotation, Post, Michigan State University, Silicon, Pittsburgh, Canavan, Private investigator, Greenberg Traurig

PHILADELPHIA, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP recently welcomed back Paul R. McIntyre to its Environmental Practice in the firm's Philadelphia office.

Key Points: 
  • Global law firm Greenberg Traurig, LLP recently welcomed back Paul R. McIntyre to its Environmental Practice in the firm's Philadelphia office.
  • PHILADELPHIA, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP recently welcomed back Paul R. McIntyre to its Environmental Practice in the firm's Philadelphia office .
  • McIntyre returns to Greenberg Traurig after nearly 10 years, along with Michael P. Canavan , who will join the firm as of counsel.
  • "I am thrilled that Paul decided to return home to Greenberg Traurig, now as an even more deeply experienced leader in environmental transactions in the real estate and private equity space," said Curtis B.

Myrtelle Announces Positive Data for Its investigational Proprietary rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay Sachs & Allied Diseases Association Conference

Retrieved on: 
Friday, July 8, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Cell, FIH, Inc., Mutation, Science, Intracerebroventricular injection, Boonshoft School of Medicine, Patient, ICV, Magnetic resonance imaging, Brain, Trial of the century, Walking, Metabolism, Disease, Intellectual property, White matter, Irritability, Forward-looking statement, Spasticity, Magnetic resonance, ASPA, Gross, Canavan disease, Kaay Raav Tumhi, MPH, Pfizer, N-Acetylaspartic acid, Clinical trial, Wright, OH, Doctor of Philosophy, Seizure, Pediatrics, CD, Time, Associate, Safety, MRI, VG, Program, NAA, Neurodegeneration, Conference, Pharmaceutical industry, Medical imaging, Canavan, Myrtelle Canavan, Aspartoacylase, MD

In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).

Key Points: 
  • In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).
  • These improvements suggest the gene therapy and the route of administration are directly targeting the oligodendrocytes, the key cells affected in Canavan disease.
  • Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases.
  • The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches for neurodegenerative diseases.

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, March 3, 2022
Failure, Operationalization, Cohort, Security (finance), Webcast, U.S. Securities and Exchange Commission, Partnership, Nasdaq, Private Securities Litigation Reform Act, Gene, Adult, PASG, IDMC, Company, SEC, Clinical trial, R, Risk, Administration, Investor, GTP, Krabbe disease, CNS, GM1, IND, Infant, Patient, Science, Central nervous system, Safety, University, Goal, Research and development, Temporal lobe epilepsy, Canavan disease, GLOBE, Amyotrophic lateral sclerosis, Pharmaceutical industry, Medical device, Lithium, Canavan

ET

Key Points: 
  • ET
    PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.
  • We are also excited to advance our robust and differentiated CNS pipeline in partnership with Penns Gene Therapy Program, Dr. Goldsmith added.
  • We are employing a diversified portfolio strategy spanning pediatric and adult CNS indications, both rare and large, to create sustained value.
  • This presentation followed the positive interim safety and biomarker data first shared by the companyin December 2021.

Compass Gives Back Supports Katie & Allie Buryk Research Fund at NTSAD

Retrieved on: 
Wednesday, December 22, 2021
Bitcoin, Conference, Program, Late-onset hypogonadism, Life, Mayo Clinic, Tay–Sachs disease, Disease, Congenital heart defect, Patient, Family, Time, Katie, CEO, Birth defect, Genetic disorder, Mentorship, Clinical professor, Mining, Lists of diseases, Investment, Sandhoff disease, Heart, CHD, Organization, HLHS, Severe cognitive impairment, Organic, Hypoplastic left heart syndrome, Paralysis, Neurology, National, Infant, GM1, Research, Multimedia, Clinical trial, Death, Speech, Partnership, Walking, Cryptocurrency, Pharmaceutical industry, Online shopping, Canavan, Compass

NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Compass Mining ("Compass"), the world's firstand largestonline marketplaceforbitcoin mining hardware,hosting,and reselling, today announced its December Compass Gives Back recipient, the Katie & Allie Buryk Research Fund , which is supported by the National Tay-Sachs & Allied Diseases Association ("NTSAD").

Key Points: 
  • NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Compass Mining ("Compass"), the world's firstand largestonline marketplaceforbitcoin mining hardware,hosting,and reselling, today announced its December Compass Gives Back recipient, the Katie & Allie Buryk Research Fund , which is supported by the National Tay-Sachs & Allied Diseases Association ("NTSAD").
  • Compass will be donating $25,000 in bitcoin to support research leading towards effective treatments for Late Onset Tay-Sachs disease, which affects twin sisters Katie and Allie Buryk.
  • Katie Buryk describes how the disease changed her life, "Sometimes I fall when I'm walking.
  • "And thanks to Compass Mining, whose Gives Back program prompted us to accept donations of cryptocurrency to support our mission and families."

Tech Sales Leader Dana Canavan Joins DAS42 in New Vice President of Sales Role

Retrieved on: 
Friday, October 22, 2021
Consulting, Data Management, Professional Services, Technology, Software, Twitter, Organization, Health, Canavan, Technology, Insurance, LinkedIn, YouTube, Growth, Retail

DAS42, a provider of modern data stack technology implementation and advisory services, is pleased to welcome Dana Canavan as the firms Vice President of Sales.

Key Points: 
  • DAS42, a provider of modern data stack technology implementation and advisory services, is pleased to welcome Dana Canavan as the firms Vice President of Sales.
  • In her new role, Canavan will spearhead the firms sales strategy development and tactical implementation, with a special focus on strengthening alignment with DAS42s data technology partners.
  • As we scale for rapid growth, having a dedicated sales team led by a seasoned Sales VP is critically important, said DAS42 CEO Nick Amabile.
  • Before joining DAS42, Canavan held several senior sales leadership positions at Acorio, including directing the enterprise sales team in the East region of the United States.

Canavan Disease Pipeline Review, H1 2020 Featuring Three Companies & Six Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, September 21, 2020
Health, Other Health, Health, Rare diseases, Lipid storage disorders, Organ systems, Canavan disease, Leukodystrophies, Canavan, Mechanism of action

Canavan Disease - Pipeline Review, H1 2020, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Key Points: 
  • Canavan Disease - Pipeline Review, H1 2020, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.
  • Canavan Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects.
  • The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

GI Partners Invests in Blue Stream Fiber

Retrieved on: 
Tuesday, June 2, 2020
Blue Stream, Coral Springs, Florida, Canavan

SAN FRANCISCO, NEW YORK, and CORAL SPRINGS, Fla., June 2, 2020 /PRNewswire/ --GI Partners and Blue Stream Fiber ("Blue Stream" or the "Company"), today jointly announced that GI Partners, in partnership with the Company's CEO, Joe Canavan, has acquired a majority interest in Blue Stream from Twin Point Capital.

Key Points: 
  • SAN FRANCISCO, NEW YORK, and CORAL SPRINGS, Fla., June 2, 2020 /PRNewswire/ --GI Partners and Blue Stream Fiber ("Blue Stream" or the "Company"), today jointly announced that GI Partners, in partnership with the Company's CEO, Joe Canavan, has acquired a majority interest in Blue Stream from Twin Point Capital.
  • The investment by GI Partners will support growth in the Company's existing markets, expansion throughout the state, and will strengthen and deepen Blue Stream's customer service capabilities.
  • Blue Stream is committed to drive ever-increasing levels of customer support and satisfaction, and to further differentiate our services from incumbents," said Joe Canavan, CEO of Blue Stream.
  • Blue Stream Fiber offers a superior alternative to traditional providers both in terms of network quality and customer focus," said Steve Smith, Managing Director of GI Data Infrastructure.